MUC1号
免疫原性
免疫疗法
医学
免疫系统
乳腺癌
临床试验
癌症
癌症免疫疗法
免疫学
肿瘤科
抗原
内科学
作者
Vasso Apostolopoulos,Geoffrey A. Pietersz,Ifc McKenzie
出处
期刊:PubMed
日期:1999-02-01
卷期号:1 (1): 98-103
被引量:22
摘要
The development of an effective immunotherapeutic approach to cancer is now a major focus of research, and despite impressive progress over the last 10 years there are still many hurdles to overcome to elicit an effective immune response which will totally eradicate the cancer. Mucins (MUC1) have attracted interest as potential targets for immunotherapy of cancers of breast, pancreas, ovary and others, and we have demonstrated that mannan, a polymannose carbohydrate is an effective carrier for MUC1 in eliciting a cellular immune response. Several clinical trials are in progress to evaluate the immunogenicity of MUC1 and its suitability as to use for immunotherapy/vaccine for breast cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI